HER2: The Neu Prognostic Marker for Breast Cancer

References

• Parker SL, Tong T, Bolden S, et al. Cancer statistics. CA: Cancer J Clin 1997; 47: 5–27.
   Google Scholar
• Nass SJ, Davidson NE. The biology of breast cancer. Hematol Oncol Clin North Am 1999; 13: 311–332.
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177–182.
   Google Scholar
• Berger MS, Locher GW, Saurer S, et al. Correlation of c-erb-b2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238–1243.
   Google Scholar
• van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. N Engl J Med 1988; 319: 1239–1245.
   Google Scholar
• Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer 1990; 65: 1794–1800.
   Google Scholar
• Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res 1990; 50: 4332–4337.
   Google Scholar
• Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the Nations Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erb B2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103–112.
   Google Scholar
• Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944–948.
   Google Scholar
• McCann AH, Dervan TA, O'Regan M, et al. Prognostic significance of c-erb B2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 3296–3303.
   Google Scholar
• Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erb B2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991; 51: 556–567.
   Google Scholar
• Noguchi M, Koyasaki M, Ohta N, et al. c-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 1992; 69: 2953–2960.
   Google Scholar
• Tiwari RK, Borgen PI, Wong GY, et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992; 12: 419–426.
   Google Scholar
• Barnes DM. c-erbB-2 amplification in mammary carcinoma. J Cell Biochem 1993; 17G(Suppl): 132–138.
   Google Scholar
• Seshadri R, Firgaira FA, et al. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993; 11: 1936–1942.
   Google Scholar
• De Potter CR. The neu-Oncogene: more than a prognostic indicator. Hum Pathol 1994; 25: 1264–1268.
   Google Scholar
• Lonn U, Lonn S, Nilsson B, et al. Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer 1995; 75: 2681–2687.
   Google Scholar
• Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of Her-2/neu expression in patients with axillary lymph node-negative breast carcinoma: a study of epidemiologic risk factors, histologic features and prognosis. Cancer 1995; 75: 1320–1326.
   Google Scholar
• Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study of 942 cases. Breast Cancer Res Treat 1995; 35: 283–291.
   Google Scholar
• Eissa S, Khalifa A, el-Gharib A, et al. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res 1997; 17: 3091–3097.
   Google Scholar
• Jennings BA, Hadfield JE, Worsley SD, et al. A differential PCR assay for the detection of c-erbB2 amplification used in a prospective study of breast cancer. J Clin Pathol: Mol Pathol 1997; 50: 254–256.
   Google Scholar
• Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462–469.
   Google Scholar
• Shih C, Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261–264.
   Google Scholar
• Padhy LC, Shih C, Cowing D, et al. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982; 28: 865–871.
   Google Scholar
• Schechter AL, Hung M-C, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229: 976–978.
   Google Scholar
• Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132–1139.
   Google Scholar
• Wosikowski K, Schuurhuis D, Johnson K, et al. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 1997; 89: 1505–1515.
   Google Scholar
• Rajkumar T, Gullick WJ. The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994; 29: 3–9.
   Google Scholar
• Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230–234.
   Google Scholar
• Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649–657.
   Google Scholar
• Akiyama T, Matsuda S, Namba Y, et al. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation of the carboxy-terminal domain. Mol Cell Biol 1991; 11: 833–842.
   Google Scholar
• Kokai Y, Myers JN, Wada T, et al. Synergistic interaction of p185c-neu and the EGF receptor leads transformation of rodent fibroblasts. Cell 1989; 58: 287–292.
   Google Scholar
• Goldman R, Levy RB, Peles E, et al. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 1990; 29: 11024–11028.
   Google Scholar
• King CR, Swain SM, Porter L, et al. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res 1989; 49: 4185–4191.
   Google Scholar
• Iglehart JD, Kraus MH, Langton BC, et al. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990; 50: 6701–6707.
   Google Scholar
• Parkes HC, Lillycrop K, Howard A, et al. C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 1990; 61: 39–45.
   Google Scholar
• Benz CC, O'Hagan RC, Richter B, et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997; 15: 1513–25.
   Google Scholar
• O'Hagan RC, Hassell JA. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 1998; 16: 301–10.
   Google Scholar
• Macleod K, Leprince D, Stehelin D. The ets gene family. Trends Biochem Sci 1992; 17: 251–256.
   Google Scholar
• Seth A, Ascione R, Fisher RJ, et al. The ets gene family. Cell Growth Differ 1992; 3: 327–34.
   Google Scholar
• Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem 1993; 211: 7–18
   Google Scholar
• Kallioniemi OP, Holli K, Visarkopi T, et al. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long term survival in breast cancer. Int J Cancer 1991; 49: 650–655.
   Google Scholar
• Molland JG, Barraclough BH, Gebski V, et al. Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer. Aust NZ J Surg 1996; 66: 64–70.
   Google Scholar
• Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53: 4960–4970.
   Google Scholar
• Tandon AK, Clark GM, Clamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120–1128.
   Google Scholar
• Paik S, Hazan R, Fisher ER, et al. Pathologic findings of the NSABP: prognostic significance of c-erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103–112.
   Google Scholar
• Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast cancer with clinical follow up. Cancer Res 1989; 49: 7147–7152.
   Google Scholar
• Clark GM, McGuire WL. Follow up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944–948.
   Google Scholar
• Roh H, Pippin J, Boswell C, et al. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surgical Res 1998; 77: 85–90.
   Google Scholar
• Drebin JA, Link VC, Stern DF, et al. Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985; 41: 697–706.
   Google Scholar
• Drebin JA, Link VC, Stern DF, et al. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene encoded tumor antigen. Proc Natl Acad Sci USA 1986; 83: 9129–9133.
   Google Scholar
• Hudziak RM, Lewis GD, Winget E, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165–1172.
   Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recom-binant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–744.
   Google Scholar
• Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor enhanced chemosensi-tivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–2671.
   Google Scholar
• Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor enhanced chemosensitiv-ity. Semin Oncol 1999; 26(Suppl 12): 89–95.
   Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly IV trastuzumab in patients with HER-2 overexpressing metastatic breast cancer. Semin Oncol 1999; 26(4 Suppl 12): 78–83.
   Google Scholar
• Stancovski I, Hurwitz E, Leitner D, et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB-2 receptor on tumor growth. Proc Natl Acad Sci 1991; 88: 8691–8695.
   Google Scholar
• Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 255–263.
   Google Scholar
• Carter P, Presta L, Gorman CM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285–4289.
   Google Scholar
• Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992; 89: 5321–5325.
   Google Scholar
• Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997; 10: 720–727.
   Google Scholar
• Gerdes AM, Nielson O, Mohr U, et al. Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2. Anticancer Res 1998; 18: 2529–2534.
   Google Scholar
• Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996; 88: 10541059.
   Google Scholar
• Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998; 51: 370–374.
   Google Scholar
• Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994; 173: 65–75.
   Google Scholar
• Tervahauta AI, Syrjanen SM, Kallio PJ, et al. Immunohistochemistry, in situ hybridization and polymerase chain reaction (PCR) in detecting c-myc expression in human malignancies. Anticancer Res 1992; 12: 1005–1012.
   Google Scholar
• Bacus SS, Chin D, Yarden Y, et al. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 1996; 148: 549–558.
   Google Scholar
• Epstein RJ, Druker BJ, Roberts TM, et al. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci USA 1992; 89: 10435–10439.
   Google Scholar
• Ottestad L, Andersen TI, Nesland JM, et al. Amplification of c-erB-2, int-2 and c-myc genes in node-negative breast carcinomas. Acta Oncolog 1993; 32: 289–294.
   Google Scholar
• Gaffey MJ, Frierson Jr HF, Williams ME. Chromosome 11 q13, c-erbB-2 and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Mod Pathol 1993; 6: 654–659.
   Google Scholar
• Yamashita H, Kobayashi S, Iwase H, et al. Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res 1993; 84: 871–878.
   Google Scholar
• Farkas DH, Long JC, Schulz R, et al. Laboratory analysis for HER-2/neu gene amplification and protein expression. Labor Med 1993; 24: 557–561.
   Google Scholar
• Farkas DH, McMahon LW, Cai P, et al. Improved quantitation of HER-2/neu gene copy number in breast tumor derived DNA samples. Am J Clin Pathol 1993; 100: 444–450.
   Google Scholar
• Johnson RC, Ricci Jr A, Cartun RW, et al. Clinical laboratory evaluation of erbB-2 oncogene amplification in primary human breast cancer. Eur J Labor Med 1998; 6: 156–160.
   Google Scholar
• Johnson RC, Ricci Jr A, Cartun RW, et al. Evaluation of p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods. Cancer Invest 2000; 18: 336–342.
   Google Scholar
• Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 1989; 4: 1153–1157.
   Google Scholar
• Szollosi J, Balazs M, Feuerstein BG, et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 1995; 55: 5400–5407.
   Google Scholar
• Diviacco S, Norio P, Zentilin L, et al. A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. Gene 1992; 122: 313–320.
   Google Scholar
• An HX, Niederacher D, Beckmann MW, Gohring UJ, Scharl A, Picard F, et al. ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer 1995; 64: 291–297.
   Google Scholar
• Edorh A, Parache RM, N'Sossani B, et al. Determination of amplification level of the c-erbB-2 protooncogene in human breast carcinomas: a comparative study between nonradioactive and radioactive labeling. Cell Mol Biol 1995; 41: 967–973.
   Google Scholar
• Fernandez JL, Goyanes V, Lopez-Fernandez C, et al. Quantification of C-ERB-B2 gene amplification in breast cancer cells using fluorescence in situ hybridization and digital image analysis. Cancer Genet Cytogenet 1996; 86: 18–21.
   Google Scholar
• Heinrichs M, Striepecke E, Bocking A. Quantitative analysis of the neu oncogene in normal and transformed epithelial breast cells by fluorescence in situ hybridization and laser scanning microscopy. Anal Quant Cytol Histol 1994; 16: 233–239.
   Google Scholar
• Sauter G, Feichter G, Torhorst J, et al. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytologica 1996; 40: 164–173.
   Google Scholar
• Breuer B, DeVivo I, Luo JC, et al. erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol Biomarkers Prevent 1994; 3: 63–66.
   Google Scholar
• Burke HB, Hoang A, Iglehart JD, et al. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 1998; 82: 874–877.
   Google Scholar
• Isola JJ, Holli K, Oksa H, et al. Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer. Cancer 1994; 73: 652–658.
   Google Scholar
• Andersen TI, Paus E, Nesland JM, et al. Detection of c-erb B2 related proteins in sera from breast cancer patients: relationship to ERBB2 gene amplification and c-erb B2 protein overexpression in tumor. Acta Oncol 1995; 34: 499–504.
   Google Scholar
• Molina R, Jo J, Zanon G, et al. Utility of cerbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer 1996; 74: 1126–1131.
   Google Scholar
• Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum c-erbB2 protein in breast cancer patients. Breast Cancer Res Treat 1996; 40: 251–255.
   Google Scholar
• Fehm T, Maimonis P, Weitz S, et al. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997; 43: 87–95.
   Google Scholar
• Mansour OA, Zekri AR, Harvey J, et al. Tissue and serum c-erbB2 and tissue EGFR in breast carcinoma: three years follow-up. Anticancer Res 1997; 17: 3101–3106.
   Google Scholar
• Disis ML, Pupa SM, Gralow JR, et al. High titer HER-2/neu protein-specific antibody can be detected in patients with early stage breast cancer. J Clin Oncol 1997; 15: 3363–3367.
   Google Scholar
• Krainer M, Brodowicz T, Zeillinger R, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997; 54: 475–481.
   Google Scholar
• Fehm T, Maimonis P, Katalinic A, et al. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998; 55: 33–38.
   Google Scholar
• Mehta RR, McDermott JH, Hieken TJ, et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998; 16: 2409–2416.
   Google Scholar
• Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439–443.
   Google Scholar
• Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer 1994; 74: 2956–2963.
   Google Scholar
• Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049–1056.
   Google Scholar
• d'Agnano I, Bucci B, Mottolese M, et al. DNA ploidy, cell kinetics, EGFR and HER2/neu oncoprotein overexpression in primary operable breast cancer. Ann NY Acad Sci 1996; 784: 472–481.
   Google Scholar
• Winstanley J, Cooke T, Murray GD, et al. The long-term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991; 63: 447–450.
   Google Scholar
• Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434–438.
   Google Scholar
• Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599–605.
   Google Scholar
• Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 1993; 67: 625–629.
   Google Scholar
• McGuire WL, Tandon AK, Allred DC, et al. Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 1992; 70(Suppl 6): 1775-1781.
   Google Scholar
• Carlomagno C, Perrone F, Gallo C, et al. CerbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol 1996; 14: 2702–2708.
   Google Scholar
• Kumar R, Mandal M, Lipton A, et al.Overexpression of HER2 modulates Bcl-2, Bcl-XL and tamoxifen induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 1996; 2: 1215–1219.
   Google Scholar
• Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node positive breast cancer. J Natl Cancer Inst 1998; 90: 1346–1360.
   Google Scholar
• Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node positive hormone receptor negative breast cancer. J Natl Cancer Inst 1998; 90: 1361–1370.
   Google Scholar
• Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node positive early breast cancer. N Engl J Med 1994; 330: 1260–1266.
   Google Scholar
• Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/ neu overexpression in human breast cancer xenografts. Cancer Res 1998; 58: 2825–2831.
   Google Scholar
• McNeil C. Herceptin raises its sights beyond advanced breast cancer. J Natl Cancer Inst 1998; 90: 882–883.
   Google Scholar